Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496508 | 0.85 | KMT2A (0.37) | KMT2AMEN1THRBNPSR1RAB9A | |
| SCHEMBL4501912 | 0.82 | KMT2A (0.43) | KMT2AMEN1NPSR1LMNA | |
| SCHEMBL11262236 | 0.74 | MAPT (0.47) | KMT2AMEN1NPSR1LMNAMAPK1 | |
| SCHEMBL11262247 | 0.73 | HTR2C (0.34) | KMT2AMEN1THRBLMNARAD52 | |
| SCHEMBL4498347 | 0.69 | WNT3A (0.40) | KMT2AMEN1NPSR1LMNARAB9A | |
| SCHEMBL4502145 | 0.67 | HTR2C (0.41) | KMT2AMEN1NPSR1LMNARAB9A | |
| SCHEMBL11260856 | 0.62 | HDAC6 (0.43) | KMT2AMEN1NPSR1LMNARAB9A | |
| SCHEMBL11259222 | 0.61 | NPC1 (0.49) | KMT2AMEN1LMNAMAPK1RAB9A | |
| SCHEMBL11262352 | 0.60 | MAPT (0.49) | KMT2AMEN1NPSR1LMNAMAPK1 | |
| SCHEMBL7535208 | 0.60 | MAPK1 (0.50) | KMT2AMEN1LMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | claimed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-4344946-A | ANTIARTHRITICS, ANTIRHEUMATICS | BOEHRINGER INGELHEIM GMBH (DE) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | KMT2A 3467/4885MEN1 18/4885THRB 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.